PE20000348A1 - Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina - Google Patents
Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatinaInfo
- Publication number
- PE20000348A1 PE20000348A1 PE1999000217A PE00021799A PE20000348A1 PE 20000348 A1 PE20000348 A1 PE 20000348A1 PE 1999000217 A PE1999000217 A PE 1999000217A PE 00021799 A PE00021799 A PE 00021799A PE 20000348 A1 PE20000348 A1 PE 20000348A1
- Authority
- PE
- Peru
- Prior art keywords
- statin
- inhibitor
- pharmaceutical composition
- mmp
- alkyl
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 abstract 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 abstract 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 229950003040 dalvastatin Drugs 0.000 abstract 1
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN INHIBIDOR DE METALOPROTEASA DE MATRIZ DE FORMULA I, DONDE A ES FENILO, R1 ES ALQUILO, ARILO, HALOGENO, AMINO, ALCOXI; R2 ES CARBOXIALQUILCETONA, OXIMA, CARBOXIALQUILSULFONAMIDA COMO -SO2NHC(-R3)HCOOH; R3 ES ALQUILO C1-C10, ALCOXI C1-C10, SIENDO UN COMPUESTO PREFERIDO 2-(4`-BROMOBIFENIL-4-SULFONILAMINO)-3-METILBUTIRICO; b)UNA ESTATINA TAL COMO ATORVASTATINA, SIMVASTATINA, PRAVASTATINA, RIVASTATINA, MEVASTATINA, FLUINDOSTATINA, VELOSTATINA, FLUVASTATINA, DALVASTATINA, DIHIDROCOMPACTINA, COMPACTINA, CERIVASTATINA, LOVASTATINA; c)UN DILUYENTE. LA COMBINACION DE LOS COMPONENTES TIENEN UN EFECTO SINERGICO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE ANGINA DE PECHO, RIESGO CARDIACO, ATEROSCLEROSIS; RETARDANDO EL AVANCE DE LA PLACAS ATEROSCLEROTICAS EN LAS ARTERIAS CORONARIAS, CAROTIDAS, SISTEMA ARTERIAL PERIFERICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000348A1 true PE20000348A1 (es) | 2000-05-22 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000217A PE20000348A1 (es) | 1998-03-17 | 1999-03-16 | Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (es) |
| JP (1) | JP2002506818A (es) |
| KR (1) | KR20010041916A (es) |
| AR (1) | AR018113A1 (es) |
| AU (1) | AU1591699A (es) |
| BR (1) | BR9815745A (es) |
| CA (1) | CA2309588A1 (es) |
| CO (1) | CO5070670A1 (es) |
| GT (1) | GT199900039A (es) |
| HN (1) | HN1999000029A (es) |
| MY (1) | MY140504A (es) |
| NZ (1) | NZ505994A (es) |
| PA (1) | PA8469001A1 (es) |
| PE (1) | PE20000348A1 (es) |
| SV (1) | SV1999000026A (es) |
| UY (1) | UY25436A1 (es) |
| WO (1) | WO1999047138A1 (es) |
| ZA (1) | ZA992106B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| AU2005315608B2 (en) | 2004-12-15 | 2011-03-31 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors |
| JP2009514851A (ja) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
| WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123902A (en) * | 1995-11-02 | 2003-01-12 | Warner Lambert Co | PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR |
| ES2167733T3 (es) * | 1996-05-17 | 2002-05-16 | Warner Lambert Co | Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. |
-
1998
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/ko not_active Ceased
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/pt not_active Application Discontinuation
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/ja active Pending
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Ceased
- 1998-11-20 NZ NZ505994A patent/NZ505994A/xx unknown
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/es unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 CO CO99016109A patent/CO5070670A1/es unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/es not_active Application Discontinuation
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/xx unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/es not_active Application Discontinuation
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/es unknown
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/es unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/es unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999047138A1 (en) | 1999-09-23 |
| MY140504A (en) | 2009-12-31 |
| ZA992106B (en) | 1999-09-30 |
| UY25436A1 (es) | 2001-10-25 |
| CO5070670A1 (es) | 2001-08-28 |
| KR20010041916A (ko) | 2001-05-25 |
| EP1063991A1 (en) | 2001-01-03 |
| GT199900039A (es) | 2000-09-06 |
| PA8469001A1 (es) | 2002-09-17 |
| AR018113A1 (es) | 2001-10-31 |
| NZ505994A (en) | 2003-10-31 |
| JP2002506818A (ja) | 2002-03-05 |
| BR9815745A (pt) | 2000-11-14 |
| HN1999000029A (es) | 1999-09-29 |
| SV1999000026A (es) | 2000-01-18 |
| AU1591699A (en) | 1999-10-11 |
| CA2309588A1 (en) | 1999-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2022116083A5 (es) | ||
| AR018777A1 (es) | Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo. | |
| AR103624A1 (es) | Composiciones farmacéuticas para terapia de combinación | |
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| RU2012116079A (ru) | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения | |
| BG105559A (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR | |
| DK0753298T3 (da) | Synergistisk kombination, der omfatter et insulinsensibiliserende middel og en HMG-CoA-reduktaceinhibitor til behandling af arteriosklerose | |
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| JP2018504438A5 (es) | ||
| TR200302281T2 (tr) | Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| PE20001047A1 (es) | METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION | |
| PE20000017A1 (es) | Combinaciones de estatina-eter carboxialquilico | |
| DK1626716T3 (da) | Nitrooxyderivater af fluvastatin, pravastatin, cerivastatin, atorvastatin og rosuvastatin som cholesterol-sænkende midler med forbedret anti-inflammatorisk, antithrombotisk og anti-blodplade-aktivitet | |
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| PE20000348A1 (es) | Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina | |
| JP2007512347A5 (es) | ||
| JP2002508320A5 (es) | ||
| CY1105429T1 (el) | Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες | |
| BR0215602A (pt) | ésteres de boronato | |
| AR080023A1 (es) | Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa | |
| JP2007530528A5 (es) | ||
| UY29979A1 (es) | Derivados espirociclicos | |
| JP2002506818A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |